These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 7889632)
21. Changes in the metabolic clearance of vasopressin and in plasma vasopressinase throughout human pregnancy. Davison JM; Sheills EA; Barron WM; Robinson AG; Lindheimer MD J Clin Invest; 1989 Apr; 83(4):1313-8. PubMed ID: 2703533 [TBL] [Abstract][Full Text] [Related]
22. A proposed relationship between vasopressinase altered vasopressin and preeclampsia. Krege JH; Katz VL Med Hypotheses; 1990 Apr; 31(4):283-7. PubMed ID: 2192237 [TBL] [Abstract][Full Text] [Related]
23. Stimulation of rat renal medullary Na+/K(+)-ATPase by arginine vasopressin is mediated by the V2 receptor. Charlton JA; Baylis PH J Endocrinol; 1990 Nov; 127(2):213-6. PubMed ID: 2174453 [TBL] [Abstract][Full Text] [Related]
24. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system. Croiset G; De Wied D Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858 [TBL] [Abstract][Full Text] [Related]
25. Effects of arginine vasopressin (AVP) on the pituitary-thyroid axis in the rat: Evidence that endogenous AVP, acting via V1 receptors, lowers TSH blood concentration. Malendowicz LK; Spinazzi R; Nowak KW; Nussdorfer GG; Majchrzak M Int J Mol Med; 2004 Jun; 13(6):869-72. PubMed ID: 15138627 [TBL] [Abstract][Full Text] [Related]
26. Vasopressin mechanism-mediated pressor responses caused by central angiotensin II in the ovine fetus. Shi L; Guerra C; Yao J; Xu Z Pediatr Res; 2004 Nov; 56(5):756-62. PubMed ID: 15347766 [TBL] [Abstract][Full Text] [Related]
27. Monensin-resistant LLC-PK1 cell mutants are affected in recycling of the adenylate cyclase-stimulating vasopressin V2-receptor. Jans DA; Jans P; Luzius H; Fahrenholz F Mol Cell Endocrinol; 1991 Oct; 81(1-3):165-74. PubMed ID: 1797584 [TBL] [Abstract][Full Text] [Related]
28. Arginine-vasopressin modulates intracellular pH via V1 and V2 receptors in renal collecting duct cells. Rivarola V; Ford P; del Pilar Flamenco M; Galizia L; Capurro C Cell Physiol Biochem; 2007; 20(5):549-58. PubMed ID: 17762181 [TBL] [Abstract][Full Text] [Related]
29. Central cardiovascular effects of AVP and AVP analogs with V1, V2 and 'V3' agonistic or antagonistic properties in conscious dog. Noszczyk B; Lon S; Szczepańska-Sadowska E Brain Res; 1993 Apr; 610(1):115-26. PubMed ID: 8518919 [TBL] [Abstract][Full Text] [Related]
30. Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein. Medina P; Acuña A; Martínez-León JB; Otero E; Vila JM; Aldasoro M; Lluch S Circulation; 1998 Mar; 97(9):865-70. PubMed ID: 9580082 [TBL] [Abstract][Full Text] [Related]
31. Comparison of selective arginine vasopressin V1 and V2 receptor antagonists on burn shock in the rat. Sun K; Lin BC; Wang CH; Zhu HN Cardiovasc Res; 1991 Apr; 25(4):265-9. PubMed ID: 1884385 [TBL] [Abstract][Full Text] [Related]
32. [Arginine]vasopressin hydrolyses phosphoinositides in the medullary thick ascending limb of mouse nephron. Baudouin-Legros M; Bouthier M; Teulon J Pflugers Arch; 1993 Dec; 425(5-6):381-9. PubMed ID: 8134254 [TBL] [Abstract][Full Text] [Related]
33. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs. Liard JF Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987 [TBL] [Abstract][Full Text] [Related]
34. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. Aki Y; Tamaki T; Kiyomoto H; He H; Yoshida H; Iwao H; Abe Y J Cardiovasc Pharmacol; 1994 Feb; 23(2):331-6. PubMed ID: 7511766 [TBL] [Abstract][Full Text] [Related]
35. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors. Feng JJ; Arendshorst WJ Am J Physiol; 1996 Aug; 271(2 Pt 2):F304-13. PubMed ID: 8770161 [TBL] [Abstract][Full Text] [Related]
36. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors. Yamauchi T; Ogura T; Oishi T; Harada K; Hashimoto M; Mimura Y; Asano N; Ota Z; Kageyama J Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410 [TBL] [Abstract][Full Text] [Related]
37. N-glycosylation plays a role in biosynthesis and internalization of the adenylate cyclase stimulating vasopressin V2-receptor of LLC-PK1 renal epithelial cells: an effect of concanavalin A on binding and expression. Jans DA; Jans P; Luzius H; Fahrenholz F Arch Biochem Biophys; 1992 Apr; 294(1):64-9. PubMed ID: 1532296 [TBL] [Abstract][Full Text] [Related]
38. Congestive heart failure in rats is associated with increased collecting duct vasopressin sensitivity and vasopressin type 2 receptor reexternalization. Brønd L; Müllertz KM; Torp M; Nielsen J; Graebe M; Hadrup N; Nielsen S; Christensen S; Jonassen TE Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1547-54. PubMed ID: 24089411 [TBL] [Abstract][Full Text] [Related]
39. Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Mizutani S; Safwat MA; Goto K; Tsujimoto M; Nakazato H; Itakura A; Mizuno M; Kurauchi O; Kikkawa F; Tomoda Y Regul Pept; 1995 Nov; 59(3):371-8. PubMed ID: 8577942 [TBL] [Abstract][Full Text] [Related]
40. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes. Torres BA; Johnson HM J Immunol; 1988 Apr; 140(7):2179-83. PubMed ID: 2965181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]